- Home
- KMDA vs ESPR Comparison
KMDA vs ESPR Comparison
Compare KMDA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- ESPR
- Stock Information
- Founded
- KMDA 1990
- ESPR 2008
- Country
- KMDA Israel
- ESPR United States
- Employees
- KMDA N/A
- ESPR N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- ESPR Health Care
- Exchange
- KMDA Nasdaq
- ESPR Nasdaq
- Market Cap
- KMDA 310.1M
- ESPR 319.2M
- IPO Year
- KMDA N/A
- ESPR 2013
- Fundamental
- Price
- KMDA $5.97
- ESPR $2.33
- Analyst Decision
- KMDA Strong Buy
- ESPR Buy
- Analyst Count
- KMDA 2
- ESPR 4
- Target Price
- KMDA $14.50
- ESPR $8.17
- AVG Volume (30 Days)
- KMDA 40.9K
- ESPR 3.4M
- Earning Date
- KMDA 11-13-2024
- ESPR 11-07-2024
- Dividend Yield
- KMDA N/A
- ESPR N/A
- EPS Growth
- KMDA 230.67
- ESPR N/A
- EPS
- KMDA 0.25
- ESPR N/A
- Revenue
- KMDA $154,574,000.00
- ESPR $295,451,000.00
- Revenue This Year
- KMDA $14.85
- ESPR $199.60
- Revenue Next Year
- KMDA $7.64
- ESPR $19.36
- P/E Ratio
- KMDA $22.94
- ESPR N/A
- Revenue Growth
- KMDA 6.01
- ESPR 187.12
- 52 Week Low
- KMDA $4.58
- ESPR $0.87
- 52 Week High
- KMDA $6.53
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- KMDA 77.16
- ESPR 54.58
- Support Level
- KMDA $5.84
- ESPR $2.05
- Resistance Level
- KMDA $6.06
- ESPR $2.25
- Average True Range (ATR)
- KMDA 0.12
- ESPR 0.12
- MACD
- KMDA 0.07
- ESPR -0.00
- Stochastic Oscillator
- KMDA 91.57
- ESPR 61.54
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.